Selective Dopamine D1 and D2 Receptor Antagonists

  • J. Hyttel
  • J. Arnt
  • M. van den Berghe
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 7)

Abstract

The concept of selective dopamine D1 and D2 receptor antagonists is rather new. Previously, dopamine receptor antagonism was evaluated simply as the ability to inhibit dopamine- or dopamine agonist-mediated behaviour or biochemical responses. In 1979 Kebabian and Calne introduced the dopamine D1 and D2 receptor concept based on differential linkage to adenylate cyclase. At that time receptor binding techniques had already been introduced, and more or less selective ligands were available (Iversen 1978). Today, very selective ligands are used to differentiate the two dopamine receptor populations.

Keywords

Scopolamine Phenothiazine Ketanserin Sulpiride Benzamides 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen PH, Gronvald C (1986) Specific binding of 3H-SCH 23390 to dopamine D1 receptors in vivo. Life Sci 38: 1507–1515PubMedCrossRefGoogle Scholar
  2. Andersen PH, Gronvald FC, Aas Jansen J (1985) A comparison between dopamine- stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum. Life Sci 37: 1971–1983PubMedCrossRefGoogle Scholar
  3. Amt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats. Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 51: 321–329Google Scholar
  4. Arnt J (1983) Neuroleptic inhibition of 6,7-ADTN-indueed hyperactivity after injection into the nucleus accumbens. Specificity and comparison with other models. Eur J Pharmacol 90: 47–55PubMedCrossRefGoogle Scholar
  5. Amt J (1985) Behavioral stimulation is induced by separate D-l and D-2 receptor sites in reserpine-pretreated but not in normal rats. Eur J Pharmacol 113: 79–88CrossRefGoogle Scholar
  6. Amt J, Christensen AV (1981) Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics. Eur J Pharmacol 69: 107–111CrossRefGoogle Scholar
  7. Amt J, Hyttel J (1984) Differential inhibition by dopamine D-l and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6- hydroxydopamine lesions. Eur J Pharmacol 102: 349–354CrossRefGoogle Scholar
  8. Amt J, Hyttel J (1985) Differential involvement of dopamine D-l and D-2 receptors in the circling behaviour induced by apomorphine, SK F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats. Psychopharmaeology (Berlin) 85: 346–352CrossRefGoogle Scholar
  9. Amt J, Hyttel J (1986) Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-l and D-2 receptor affinities in vitro. J Neural Transm 67: 225–240CrossRefGoogle Scholar
  10. Amt J, Hyttel J (1988) Behavioral differentiation between effects elicited at dopamine D-l and D-2 receptors in rats with normosensitive DA receptors. Pharmacopsychiatry 21: 24–27CrossRefGoogle Scholar
  11. Arnt J, Hyttel J, Larsen J-J (1984) The citalopram/5-HTP-induced head shake syndrome is correlated to 5-HT2 receptor affinity and also influenced by other transmitters. Acta Pharmacol Toxicol (Copenh) 55: 363–372CrossRefGoogle Scholar
  12. Arnt J, Bøgesø KP, Hyttel J ( 1988 a) Dopamine D-l and D-2 receptor differentiation revealed by behavioural studies in rats. In: Beart P, Jackson D, Woodruff GN (eds) Pharmacology and functional regulation of dopaminergic neurons. Macmillan, London, p110–116Google Scholar
  13. Arnt J, Bøgesø KP, Boeck V, Christensen AV, Dragsted N, Hyttel J, Skarsfeldt T (1989) In vivo pharmacology of irindalone, a 5-HT2 receptor antagonist with predominant peripheral effects. Drug Dev Res 16: 59–70CrossRefGoogle Scholar
  14. Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A (1984) Characterization of the binding of 3H-SCH 23390, a selective D-l-receptor antagonist ligand, in rat striatum. Life Sci 35: 1885–1893PubMedCrossRefGoogle Scholar
  15. Bunney BS (1984) Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends Neurosci 7: 212–215CrossRefGoogle Scholar
  16. Christensen AV, M0ller Nielsen I (1980) On the supersensitivity of DA receptors after single and repeated administration of neuroleptics. In: Smith RC (ed) Tardive dyskinesia, research and treatment. Spectrum, New York, pp 35–50Google Scholar
  17. Christensen AV, Fjalland B, M0ller Nielsen I (1976) On the supersensitivity of dopamine receptors, induced by neuroleptics. Psychopharmacology (Berlin) 48: 1–6CrossRefGoogle Scholar
  18. Christensen AV, Amt J, Hyttel J, Larsen J-J, Svendsen O (1984 a) Pharmacological effects of a specific dopamine D-l antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34: 1529–1540Google Scholar
  19. Christensen AV, Amt J, Svendsen O ( 1984 b) Animal models for neuroleptic-induced neurological dysfunction. In: Usdin E, Carlsson A, Dahlström A, Engel J (eds) Catecholamines: neuropharmacology and central nervous system - therapeutic aspects. Liss, New York, pp 99–109Google Scholar
  20. Christensen AV, Amt J, Hyttel J, Svendsen O (1984c) Behavioural correlates to the dopamine D-l and D-2 antagonists. Pol J Pharmacol Pharm 36: 249–264PubMedGoogle Scholar
  21. Christensen AV, Amt J, Svendsen O (1985) Pharmacological differentiation of dopamine D- 1 and D-2 antagonists after single and repeated administration. Psychopharmacology (Berlin) [Suppl] 2: 182–190CrossRefGoogle Scholar
  22. Clark D, White FJ (1987) Review: D1 dopamine receptor - the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1: 347–388PubMedCrossRefGoogle Scholar
  23. Claveria LE, Teychenne PF, Calne DB, Haskayne L, Petrie A, Pallis CA, Lodge-Patch IC (1975) Tardive dyskinesia treated with pimozide. J Neurol Sci 24: 393–404PubMedCrossRefGoogle Scholar
  24. Coward DM (1983) Apomorphine-induced biphasic- circling behaviour in 6-hydroxydopamine-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol 323: 49–53CrossRefGoogle Scholar
  25. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483PubMedCrossRefGoogle Scholar
  26. Farde L (1987) Dopamine receptor characteristics in the living human brain. Thesis, University of StockholmGoogle Scholar
  27. Fleminger S, Rupniak NMJ, Hall MD, Jenner P, Marsden CD (1983) Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-l receptors. Biochem Pharmacol 32: 2921–2927PubMedCrossRefGoogle Scholar
  28. Gerlach J, Simmelsgaard H (1978) Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine and clozapine. Psychopharmacology (Berlin) 59: 105–112CrossRefGoogle Scholar
  29. Gower AJ, Marriott AS (1982) Pharmacological evidence for the subclassification of central dopamine receptors in the rat. Br J Pharmacol 77: 185–194PubMedGoogle Scholar
  30. Hayashi T, Tadokoro S (1984) Parallelism between avoidance-suppressing and prolactin- increasing effects of antipsychotic drugs in rats. Jpn J Pharmacol 35: 451–456PubMedGoogle Scholar
  31. Heikkila L, Laitinen J, Vartiainen H (1981) Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation. Acta Psychiatr Scand [Suppl 294] 64: 30–38Google Scholar
  32. Herrera-Marschitz M, Ungerstedt U (1984) Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. Eur J Pharmacol 98: 165–176PubMedCrossRefGoogle Scholar
  33. Hyttel J (1978) Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)-flupenthixol binding and on adenylate cyclase activity in vitro. Life Sci 23: 551–556PubMedCrossRefGoogle Scholar
  34. Hyttel J (1981) Similarities between the binding of 3H-piflutixol and 3H-flupenthixol to rat striatal dopamine receptors in vitro. Life Sci 28: 563–569PubMedCrossRefGoogle Scholar
  35. Hyttel J (1982) Preferential labelling of adenylate cyclase coupled dopamine receptors with thioxanthene neuroleptics. In: Kohsaka M, Shohmori T, Tsukada Y, Woodruff GN (eds) Advances in dopamine research. Pergamon, Oxford, pp 147–152 (Advances in the biosciences, vol 37 )Google Scholar
  36. Hyttel J (1983) SCH 23390 - the first selective dopamine D-l antagonist. Eur J Pharmacol 91: 153–154PubMedCrossRefGoogle Scholar
  37. Hyttel J, Arnt J (1987) Characterization of binding of 3H-SCH 23390 to dopamine D-l receptors. Correlation to other D-l and D-2 measures and effect of selective lesions. J Neural Transm 68: 171–189PubMedCrossRefGoogle Scholar
  38. Hyttel J, Larsen J-J, Christensen AY, Arnt J (1985) Receptor-binding profiles of neuroleptics. Psychopharmacology (Berlin) [Suppl] 2: 9–18CrossRefGoogle Scholar
  39. Iversen LL (1978) More than one type of dopamine receptor in brain? Trends Neurosci 1: V–VIGoogle Scholar
  40. Jenner P, Marsden D (1987) Neuroleptic-induced tardive dyskinesia. Acta Psychiatr Belg 87: 566–598PubMedGoogle Scholar
  41. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  42. Kuny S, Woggon B (1984) Cis(Z)-clopenthixol in the treatment of acute schizophrenia. In: Hall P (ed) Proceedings of the symposium “Modern trends in the chemotherapy of schizophrenia”. VII World Congress of Psychiatry, Vienna. H. Lundbeck A/S, Copenhagen, pp 13–24Google Scholar
  43. Leysen JE, Gommeren W, Laduron PM (1978) Spiperone: a ligand of choice for neuroleptic receptors. I. Kinetics and characteristics of in vitro binding. Biochem Pharmacol 27: 307–316PubMedCrossRefGoogle Scholar
  44. Leysen JE, van Gompel P, Gommeren W, Laduron PM (1987) Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone. In: Dahl S, Gram L, Paul S, Potter W (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 214–224 (Psychopharmacology series, vol 3 )Google Scholar
  45. Molloy AG, Waddington JL (1985 a) Sniffing, rearing and locomotor responses to the D-l dopamine agonist R-SK F 38393 and to apomorphine: differential interactions with the selective D-l and D-2 antagonists SCH 23390 and metoclopramide. Eur J Pharmacol 108: 305–308Google Scholar
  46. Molloy AG, Waddington JL (1985 b) The enantiomer of SK F 83566, a new selective D-l dopamine antagonist, stereospecifically blocks stereotyped behaviour induced by apomorphine and by the selective D-2 agonist RU 24213. Eur J Pharmacol 116: 183–186Google Scholar
  47. Niemegeers CJE, Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24: 2201–2216PubMedCrossRefGoogle Scholar
  48. Niemegeers CJE, Colpaert FC, Leysen JE, Awouters F, Janssen PAJ (1983) Mescaline- induced head-twitches in the rat: an in vivo method to evaluate serotonin S2 antagonists. Drug Dev Res 3: 123–135CrossRefGoogle Scholar
  49. Nordic Dyskinesia Study Group (1986) Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology (Berlin) 90: 423–429CrossRefGoogle Scholar
  50. O’Boyle K, Waddington JL (1984) Identification of the enantiomers of SK F 83566 as specific and stereoselective antagonists at the striatal D-l dopamine receptor: comparisons with the D-2 enantioselectivity of Ro 22-1319. Eur J Pharmacol 106: 219–220PubMedCrossRefGoogle Scholar
  51. O’Boyle KM, Pugh M, Waddington JL (1984) Stereotypy induced by the D-2 agonist RU 24213 is blocked by the D-2 antagonist Ro 22-2586 and the D-l antagonist SCH 23390. Br J Pharmacol 82: 242 PGoogle Scholar
  52. Peroutka S J, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, a-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522PubMedGoogle Scholar
  53. Pollak P, Gaio J-M, Hommel M, Pellat J, Perret J (1985) Effect of tiapride in tardive dys-kinesia. Psychopharmacology (Berlin) 85: 236–239CrossRefGoogle Scholar
  54. Rosengarten H, Schweitzer JW, Friedhoff AJ (1983) Induction of oral dyskinesias in naïve rats by D1 stimulation. Life Sci 33: 2479–2482PubMedCrossRefGoogle Scholar
  55. Rosengarten H, Schweitzer JW, Friedhoff AJ (1986) Selective dopamine D2 receptor reduction enhances a D1 mediated oral dyskinesia in rats. Life Sci 39: 29–35PubMedCrossRefGoogle Scholar
  56. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313PubMedGoogle Scholar
  57. Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978 a) The central effects of a novel dopamine agonist. Eur J Pharmacol 50: 419–430Google Scholar
  58. Setler PE, Malesky M, McDevitt J, Turner K (1978 b) Rotation produced by administration of dopamine and related substances directly into the supersentive caudate nucleus. Life Sci 23: 1277–1284Google Scholar
  59. Skarsfeldt T (1988) Effect of chronic treatment with SCH 23390 and haloperidol on spontaneous activity of dopamine neurones in SNC and YTA in rats. Eur J Pharmacol 145: 239–243PubMedCrossRefGoogle Scholar
  60. Svendsen O, Arnt J, Boeck V, B0ges0 KP, Christensen AV, Hyttel J, Larsen J-J (1986) The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin receptor antagonistic effects. Drug Dev Res 6: 35–47CrossRefGoogle Scholar
  61. Waddington JL, Gamble S J (1980) Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration. Eur J Pharmacol 67: 363–369PubMedCrossRefGoogle Scholar
  62. Waddington JL, Gamble S J, Bourne RC (1981) Sequelae of 6 months continuous ad-ministration of cis(Z)-and trans(E)-flupenthixol in the rat. Eur J Pharmacol 69: 511–513PubMedCrossRefGoogle Scholar
  63. Wistedt B (1984) Effect of neuroleptic withdrawal during the maintenance treatment of chronic schizophrenics. In: Hall P (ed) Proceedings of the Symposium “Modern trends in chemotherapy of schizophrenia”. VII World Congress of Psychiatry, Vienna. H. Lundbeck A/S, Copenhagen, pp 44–59Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. Hyttel
    • 1
  • J. Arnt
    • 1
  • M. van den Berghe
    • 2
  1. 1.Department of PharmacologyH. Lundbeck A/SCopenhagenDenmark
  2. 2.Lundbeck NVVilvoordeBelgium

Personalised recommendations